Mauna Kea Technologies SAS
PAR:MKEA

Watchlist Manager
Mauna Kea Technologies SAS Logo
Mauna Kea Technologies SAS
PAR:MKEA
Watchlist
Price: 0.506 EUR -2.69% Market Closed
Market Cap: €24.4m

Operating Margin

-26.6%
Current
Improving
by 29.7%
vs 3-y average of -56.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-26.6%
=
Operating Income
€-3.5m
/
Revenue
€13.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-26.6%
=
Operating Income
€-3.5m
/
Revenue
€13.1m

Peer Comparison

Country Company Market Cap Operating
Margin
FR
Mauna Kea Technologies SAS
PAR:MKEA
23.5m EUR
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
187.7B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
184.6B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
135.6B USD
Loading...
US
Stryker Corp
NYSE:SYK
134.5B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
128.9B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
57B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
48.1B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.8B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
48.5B USD
Loading...
US
Resmed Inc
NYSE:RMD
36.6B USD
Loading...

Market Distribution

Lower than 85% of companies in France
Percentile
15th
Based on 2 333 companies
15th percentile
-26.6%
Low
-17 526.7% — 1.3%
Typical Range
1.3% — 11.5%
High
11.5% — 89 700%
Distribution Statistics
France
Min -17 526.7%
30th Percentile 1.3%
Median 6.1%
70th Percentile 11.5%
Max 89 700%

Mauna Kea Technologies SAS
Glance View

Market Cap
24.4m EUR
Industry
Health Care

Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2011-07-05. The firm focuses on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product is Cellvizio, a confocal laser endomicroscopy platform using microprobes and needles. This technological platform enables to view tissues at cellular level, in real time, during standard procedure. Cellvizio can be used in gastroenterology, pulmonology, or urology. The firm markets its technological platform in more than 40 countries, including the United States, Europe, Japan, China, South Korea as well as several Latin American countries.

MKEA Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-26.6%
=
Operating Income
€-3.5m
/
Revenue
€13.1m
What is Mauna Kea Technologies SAS's current Operating Margin?

The current Operating Margin for Mauna Kea Technologies SAS is -26.6%, which is above its 3-year median of -56.3%.

How has Operating Margin changed over time?

Over the last 3 years, Mauna Kea Technologies SAS’s Operating Margin has increased from -225.9% to -26.6%. During this period, it reached a low of -225.9% on May 30, 2020 and a high of -26.6% on May 1, 2023.

Back to Top